SYN-TECH Chemical & Pharmaceutical Co. Ltd. · TPEX:1777
SYN-TECH Chemical & Pharmaceutical — Industry Forum 14 Nov. 2024
20 slides from SYN-TECH Chemical & Pharmaceutical's conference presentation, Nov 14, 2024
Slide 1: Syn-tech Chem. & Pharm. Co., Ltd Industry Forum
Add You Text Here Add You Text Here 此处添加标题 SYN-TECH CHEM.& PHARM.CO.,LTD 14 Nov. 2024 Industry Forum Chen-Ming, Hsiao Chairman Stock Code：1777
Slide 2: Safe Harbor Notice
Safe Harbor Notice In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward- looking statements relate to events and depend on circumstances in the future, they
Slide 3: Contents
Add You Text Here Add You Text Here 此处添加标题 Company Brief Introduction Brief overall Main Products DMF/MF Registration Status Official and Customer Audit Records CONTENTS Business and Financial Statements Performance for operation Strategy in the Future Development & forward-looking Future strategies
Slide 4: Company Brief Introduction
Add You Text Here Add You Text Here 此处添加标题 01 Company Brief Introduction Brief overall Main Products DMF/MF Registration Status Official and Customer Audit Records
Slide 5: Brief overall
Brief overall SYN-TECH CHEM. & PHARM. CO. LTD. ⚫ 1982 , Nov. 9 established ⚫ Awards Record National Award in Medicine Quality NT$ 445,917,130 National Award of Outstanding C. M. Hsiao, Chairman Research and Development Award in 222 employees Pharmaceutical Technology National Innovatio
Slide 6: Main Products
Main Products SYN-TECH CHEM. & PHARM. CO. LTD. Product 1 Muscle Relaxants Product 6 Respiratory System Drugs Product 2 Topical Anesthetic Agents Product 7 Cardiovascular Agents Product 3 Digestive System Drugs Product 8 Chemotherapeutic Drugs Non- Steroidal Anti- Inflammatory Product 9 Antipyretics
Slide 7: DMF/MF Registration Status
DMF/MF Registration Status SYN-TECH CHEM. & PHARM. CO. LTD. COUNTRY DMF/MF (APIs) U.S.A 19 Japan 21 Canada 3 Korea 6 European Union 7 China 3 Others 9
Slide 8: Official Audit Records
Official Audit Records SYN-TECH CHEM. & PHARM. CO. LTD. Korea FDA Australia U.S.A FDA Mexico Number / Number / TGA FDA Audit：7 Audit：2 Number / Number / Audit：2 Audit：1 1995 2002 2007 2008 2009 2014 2015 2016 Taiwan FDA Hungary FDA Japan EDQM Number / Number / PMDA Number / Audit：20 Audit：1 Number /
Slide 9: Customer Audit Records
Customer Audit Records SYN-TECH CHEM. & PHARM. CO. LTD. Audit year Number / Audit 2019 25 2020 5 2021 7 2022 11 2023 35 Jan.- Oct., 2024 27
Slide 10: Business and Financial Statements
Add You Text Here Add You Text Here 此处添加标题 02 Business and Financial Statements Performance for operation
Slide 11: Revenue of Recent Years
Revenue of Recent 5 Years SYN-TECH CHEM. & PHARM. CO. LTD. Unit : NT in million 1,200 1,115 1,100 984 986 1,000 946 943 900 800 747 700 600 500 400 300 200 100 0 2019 2020 2021 2022 2023 Jan.-Sep., 2024 (retrospective adjustment)
Slide 12: Product Category Revenue Proportion
Product Category Revenue Proportion SYN-TECH CHEM. & PHARM. CO. LTD. Between 2024 and 2023 Q3 Unit : NT in ten thousand 40,000 38% 35,000 38% 30,000 25,000 20,000 15,000 16% 12% 12% 10,000 10% 9% 10% 9% 9% 6% 6% 7% 5,000 5% 4% 4% 3% 0% 1% 1% 0 Non- Steroidal Topical Central Anti- Muscle Digestive Ex
Slide 13: Sale proportion basis on the Area
Sale proportion basis on the Area SYN-TECH CHEM. & PHARM. CO. LTD. Others Taiwan Asia (Except Taiwan 1% 11% and Japan) 21% Europe 22% Japan America 30% 15% Asia (Except Taiwan and Japan) Japan America Europe Others Taiwan Data collected form Jan.- Sep., 2024
Slide 14: Revenue Compared Between 2024 and 2023 Q3
Revenue Compared Between 2024 and 2023 Q3 SYN-TECH CHEM. & PHARM. CO. LTD. Unit : NT in thousands Item Jan.- Sep., 2024 Jan.- Sep., 2023 Differences (%) Operating revenue 943,393 842,794 12 Gross profit 356,927 314,014 14 Gross profit ratio (%) 38 37 3 Operating profit 257,373 220,200 17 Non- operat
Slide 15: The Differences Between 2024 and 2023 Q3
The Differences Between 2024 and 2023 Q3 SYN-TECH CHEM. & PHARM. CO. LTD. Revenue ➢ Plant B, which was originally used to support the production of other products, has gradually restored its original product production capacity and integrated manpower to increase equipment utilization. ➢ Some produc
Slide 16: EPS and Dividend in Recent Years
EPS and Dividend in Recent 5 Years SYN-TECH CHEM. & PHARM. CO. LTD. Unit : NT in dollar 8.00 7.00 6.62 6.77 6.21 6.00 5.63 5.31 5.00 3.5 4.0 4.00 3.5 3.38 3.0 3.00 1.93 2.00 1.00 0.00 2019 2020 2021 2022 2023 Jan.-Sep., 2024 (retrospective adjustment) EPS Cash dividend
Slide 17: Strategy in the Future Development & forward-looking
Add You Text Here Add You Text Here 此处添加标题 03 Strategy in the Future Development & forward-looking Future strategies and forward-looking
Slide 18: Strategy in the Future Development & forward-looking Ⅰ
Strategy in the Future Development & SYN-TECH CHEM. & PHARM. CO. LTD. forward-looking Ⅰ IMH has been performed Process Validation in the fourth quarter, and it is expected that Japanese pharmaceutical companies will implement Process Validation in the first half year of 2025; AMH can be successfull
Slide 19: Strategy in the Future Development & forward-looking Ⅱ
Strategy in the Future Development & SYN-TECH CHEM. & PHARM. CO. LTD. forward-looking Ⅱ Carefully select and evaluate suitable new niche APIs for the future development : In accordance with national needs, products are selected to be manufactured to avoid domestic shortage of drugs. We are still co
Slide 20: Thanks for your attention
Add You Text Here Add You Text Here 此处添加标题 SYN-TECH CHEM.& PHARM.CO.,LTD Thanks for your attention Stock Code：1777
Syn-tech Chemical & Pharmaceutical — Industry Forum 14 Nov. 2024 on 6ix